Now, for millions, that signal is being switched off
The new blockbuster obesity drugs, made famous by Ozempic, are collectively known as GLP-1 agonists, for the hormone they mimic in the body: glucagon-like peptide 1
Adv Ther
Community reports describe waist circumference decreasing faster than the scale would suggest
People are drawn to microdosing for real reasons: nausea management, cost savings, and more control over their dose response
Across much of the South and Midwest, the combination of high obesity prevalence, lower wages, and limited insurance coverage creates what could be described as GLP-1 deserts regions where access is constrained not just by price, but by insurance exclusions and state-level policy decisions